Combination of caspofungin and low-dose trimethoprim/sulfamethoxazole for the treatment of severe Pneumocystis jirovecii pneumonia in renal transplant recipients

Autor:	Min-Jie Ju, Ming Xu, Yi-Zhou He, Guo-Wei Tu, Zhang-Gang Xue, Tongyu Zhu, Zhe Luo, Ruiming Rong
Rok vydání:	2013
Předmět:	medicine.medical_specialty business.industry Incidence (epidemiology) Sulfamethoxazole General Medicine urologic and male genital diseases bacterial infections and mycoses medicine.disease Trimethoprim chemistry.chemical_compound chemistry Pneumocystis carinii Nephrology Internal medicine medicine Caspofungin Complication Intensive care medicine Adverse effect business Kidney transplantation medicine.drug
Zdroj:	Nephrology. 18:736-742
ISSN:	1320-5358
DOI:	10.1111/nep.12133
Popis:	Pneumocystis jirovecii pneumonia (PJP) is a severe and life-threatening complication in immunocompromised patients. Trimethoprim/sulfamethoxazole (TMP-SMZ) is well known for its effectiveness as prophylaxis of PJP. However, the use of TMP-SMZ is associated with various adverse effects that may not be tolerated by critically ill patients. Caspofungin is recommended for invasive fungal infections, but the treatment of PJP after solid organ transplantation (SOT) is an off-label use of this drug. In this study, three cases of severe PJP in renal transplant recipients treated with a combination of caspofungin and low-dose TMP-SMZ were presented. Initial findings indicated that the combined treatment may be beneficial for the treatment of PJP and decrease the incidence of TMP-SMZ-related adverse effects.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::7f9eaf382d0a9f65af1c91a223153836 https://doi.org/10.1111/nep.12133 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.